氢化可的松改善极早产儿无支气管肺发育不良生存
该试验纳入胎龄小于30周、生后14至28天已插管至少7天的早产儿800例(平均出生体重715±167 g,平均胎龄24.9±1.5周),随机接受氢化可的松4 mg/kg/天、10天渐减或安慰剂,并设定强制拔管阈值。主要疗效终点36周矫正胎龄无中重度支气管肺发育不良生存率:氢化可的松组16.6%(66/398)vs 安慰剂组13.2%(53/402),调整率比1.27(95%CI 0.93–1.74)。主要安全终点22至26个月矫正年龄无中重度神经发育损害生存率:氢化可的松组36.9%(132/358)vs 安慰剂组37.3%(134/359),调整率比0.98(95%CI 0.81–1.18)。氢化可的松组需药物治疗的高血压更常见(4.3% vs 1.0%),其他不良事件两组相似。
要点
- 纳入胎龄小于30周、生后14至28天已插管至少7天的早产儿800例,随机接受氢化可的松4 mg/kg/天10天渐减或安慰剂。
- 36周矫正胎龄无中重度支气管肺发育不良生存率氢化可的松组16.6% vs 安慰剂组13.2%,调整率比1.27(95%CI 0.93–1.74),未达统计学显著。
- 22至26个月矫正年龄无中重度神经发育损害生存率氢化可的松组36.9% vs 安慰剂组37.3%,调整率比0.98(95%CI 0.81–1.18)。
- 氢化可的松组需药物治疗的高血压发生率4.3% vs 安慰剂组1.0%,其他不良事件两组相似。
- 该试验设定了强制拔管阈值,两岁结局随访完成率91.0%。
适用人群与场景
- 胎龄小于30周、生后14至28天已插管至少7天的早产儿,共800例(平均出生体重715±167 g,平均胎龄24.9±1.5周)。
诊断标准与关键阈值
- 主要疗效终点为36周矫正胎龄时无中重度支气管肺发育不良生存。
- 主要安全终点为22至26个月矫正年龄时无中重度神经发育损害生存。
- 试验规定了强制拔管阈值。
处置流程与药物剂量
- 氢化可的松4 mg/kg/天,10天渐减方案,用于生后14至28天已插管至少7天的早产儿。
- 对照组使用安慰剂。
红旗征与不能漏的情况
- 氢化可的松组需药物治疗的高血压发生率4.3%,高于安慰剂组1.0%。
研究设计与关键结果
- 多中心随机对照试验,纳入800例极早产儿,随机接受氢化可的松4 mg/kg/天10天渐减或安慰剂。
- 36周矫正胎龄无中重度支气管肺发育不良生存:氢化可的松组66/398(16.6%)vs 安慰剂组53/402(13.2%),调整率比1.27(95%CI 0.93–1.74)。
- 22至26个月矫正年龄无中重度神经发育损害生存:氢化可的松组132/358(36.9%)vs 安慰剂组134/359(37.3%),调整率比0.98(95%CI 0.81–1.18);两岁结局随访完成率91.0%。
- 需药物治疗的高血压:氢化可的松组4.3% vs 安慰剂组1.0%;其他不良事件两组相似。
证据类型、等级与局限
- 随机对照试验(ClinicalTrials.gov NCT01353313),由美国国立卫生研究院资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于生后14至28天已插管至少7天的极早产儿,氢化可的松4 mg/kg/天10天渐减方案未显著提高36周矫正胎龄无中重度支气管肺发育不良生存率,也未显著改变22至26个月无中重度神经发育损害生存率。
- 使用氢化可的松时需注意需药物治疗的高血压发生率高于安慰剂(4.3% vs 1.0%)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bronchopulmonary dysplasia is a prevalent complication after extremely preterm birth. Inflammation with mechanical ventilation may contribute to its development. Whether hydrocortisone treatment after the second postnatal week can improve survival without bronchopulmonary dysplasia and without adverse neurodevelopmental effects is unknown.
METHODS: We conducted a trial involving infants who had a gestational age of less than 30 weeks and who had been intubated for at least 7 days at 14 to 28 days. Infants were randomly assigned to receive either hydrocortisone (4 mg per kilogram of body weight per day tapered over a period of 10 days) or placebo. Mandatory extubation thresholds were specified. The primary efficacy outcome was survival without moderate or severe bronchopulmonary dysplasia at 36 weeks of postmenstrual age, and the primary safety outcome was survival without moderate or severe neurodevelopmental impairment at 22 to 26 months of corrected age.
RESULTS: We enrolled 800 infants (mean [±SD] birth weight, 715±167 g; mean gestational age, 24.9±1.5 weeks). Survival without moderate or severe bronchopulmonary dysplasia at 36 weeks occurred in 66 of 398 infants (16.6%) in the hydrocortisone group and in 53 of 402 (13.2%) in the placebo group (adjusted rate ratio, 1.27; 95% confidence interval [CI], 0.93 to 1.74). Two-year outcomes were known for 91.0% of the infants. Survival without moderate or severe neurodevelopmental impairment occurred in 132 of 358 infants (36.9%) in the hydrocortisone group and in 134 of 359 (37.3%) in the placebo group (adjusted rate ratio, 0.98; 95% CI, 0.81 to 1.18). Hypertension that was treated with medication occurred more frequently with hydrocortisone than with placebo (4.3% vs. 1.0%). Other adverse events were similar in the two groups.
CONCLUSIONS: In this trial involving preterm infants, hydrocortisone treatment starting on postnatal day 14 to 28 did not result in substantially higher survival without moderate or severe bronchopulmonary dysplasia than placebo. Survival without moderate or severe neurodevelopmental impairment did not differ substantially between the two groups. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01353313.).
参考来源
- Watterberg KL, Walsh MC, Li L, et al. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. N Engl J Med. 2022. PMID: 35320643. doi:10.1056/NEJMoa2114897
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。